JP2022537515A5 - - Google Patents

Info

Publication number
JP2022537515A5
JP2022537515A5 JP2021573591A JP2021573591A JP2022537515A5 JP 2022537515 A5 JP2022537515 A5 JP 2022537515A5 JP 2021573591 A JP2021573591 A JP 2021573591A JP 2021573591 A JP2021573591 A JP 2021573591A JP 2022537515 A5 JP2022537515 A5 JP 2022537515A5
Authority
JP
Japan
Prior art keywords
protein
protein according
cancer
antigen
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021573591A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022537515A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2020/095354 external-priority patent/WO2020249003A1/en
Publication of JP2022537515A publication Critical patent/JP2022537515A/ja
Publication of JP2022537515A5 publication Critical patent/JP2022537515A5/ja
Pending legal-status Critical Current

Links

JP2021573591A 2019-06-10 2020-06-10 抗体-インターロイキン融合タンパク質および使用方法 Pending JP2022537515A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/090494 2019-06-10
CN2019090494 2019-06-10
PCT/CN2020/095354 WO2020249003A1 (en) 2019-06-10 2020-06-10 Antibody-interleukin fusion protein and methods of use

Publications (2)

Publication Number Publication Date
JP2022537515A JP2022537515A (ja) 2022-08-26
JP2022537515A5 true JP2022537515A5 (cg-RX-API-DMAC7.html) 2023-06-19

Family

ID=73781610

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021573591A Pending JP2022537515A (ja) 2019-06-10 2020-06-10 抗体-インターロイキン融合タンパク質および使用方法

Country Status (6)

Country Link
US (1) US20220306713A1 (cg-RX-API-DMAC7.html)
EP (1) EP3980067A4 (cg-RX-API-DMAC7.html)
JP (1) JP2022537515A (cg-RX-API-DMAC7.html)
CN (1) CN114599390A (cg-RX-API-DMAC7.html)
CA (1) CA3143218A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020249003A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115279793B (zh) * 2020-05-14 2025-12-23 安立玺荣生医(香港)有限公司 抗pd-l1抗体和抗pd-l1/il10融合蛋白
CN117377767A (zh) * 2021-03-10 2024-01-09 免疫苏醒公司 免疫调节分子及其用途
EP4294927A2 (en) * 2021-03-10 2023-12-27 Immunowake Inc. Immunomodulatory molecules and uses thereof
CN115838424A (zh) * 2021-09-22 2023-03-24 上海康岱生物医药技术股份有限公司 靶向tigit的单克隆抗体
KR20240074772A (ko) * 2021-10-10 2024-05-28 엘릭시론 이뮤노테라퓨틱스 (홍콩) 리미티드 항-pd-l1/il-10 융합 단백질을 이용한 질병 치료 방법
EP4414381A4 (en) * 2021-11-02 2025-01-22 Guangdong Fapon Biopharma Inc. MONOMERIC FUSION PROTEIN OF IL-10 AND ITS USE
WO2024131864A1 (zh) * 2022-12-21 2024-06-27 广东菲鹏制药股份有限公司 一种il-10单体融合蛋白
EP4786499A1 (en) * 2023-10-08 2026-08-05 Guangdong Fapon Biopharma Inc. Anti-pd1-il10 fusion protein and use thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009298131B2 (en) * 2008-10-02 2016-07-14 Aptevo Research And Development Llc CD86 antagonist multi-target binding proteins
KR20160079114A (ko) * 2013-11-11 2016-07-05 아르모 바이오사이언시스 인코포레이티드 질환 및 장애를 치료하기 위한 인터류킨-10을 사용하는 방법
BR112016016658A2 (pt) * 2014-02-06 2018-01-23 F. Hoffmann-La Roche Ag proteína de fusão de um anticorpo, polinucleotídeo, vetor, célula hospedeira, composição farmacêutica, métodos para produzir uma proteína de fusão e de tratamento de uma doença em um indivíduo e uso da proteína de fusão
KR102524920B1 (ko) * 2014-07-22 2023-04-25 아폴로믹스 인코포레이티드 항-pd-1 항체
SG10201901057UA (en) * 2014-08-05 2019-03-28 Cb Therapeutics Inc Anti-pd-l1 antibodies
CN109071632B (zh) * 2016-02-05 2022-12-30 奥里尼斯生物科学私人有限公司 靶向性治疗剂及其用途
CN111315398A (zh) * 2017-11-10 2020-06-19 阿尔莫生物科技股份有限公司 白介素-10与免疫检查点途径抑制剂的组合的组合物和使用方法

Similar Documents

Publication Publication Date Title
Tapia-Galisteo et al. Bi-and trispecific immune cell engagers for immunotherapy of hematological malignancies
JP2022159548A5 (cg-RX-API-DMAC7.html)
JP2020103301A5 (cg-RX-API-DMAC7.html)
JP2022177097A (ja) ヘテロ二量体多重特異性抗体フォーマット
RU2017145150A (ru) Антитело против pdl-1, его фармацевтическая композиция и применение
Feldmann et al. Novel humanized and highly efficient bispecific antibodies mediate killing of prostate stem cell antigen-expressing tumor cells by CD8+ and CD4+ T cells
JP2022515318A5 (cg-RX-API-DMAC7.html)
RU2017115315A (ru) Антитела к рецептору глюкокортикоид-индуцированного фактора некроза опухоли (gitr) и способы их применения
JP2017531427A5 (cg-RX-API-DMAC7.html)
JP2019532619A5 (cg-RX-API-DMAC7.html)
JP2020534830A5 (cg-RX-API-DMAC7.html)
RU2022102446A (ru) Биспецифические связывающие белки и пути их применения
JP2019531697A5 (cg-RX-API-DMAC7.html)
ES3036457T3 (en) A cd33-, cd16- and cd123-specific single chain triplebody
JP2021516051A5 (cg-RX-API-DMAC7.html)
JP2021530244A5 (cg-RX-API-DMAC7.html)
JP2022512891A5 (cg-RX-API-DMAC7.html)
JP2022519120A5 (cg-RX-API-DMAC7.html)
CN115461373A (zh) 密蛋白18.2的抗体及其用途
JP2023510429A5 (cg-RX-API-DMAC7.html)
JP2015520172A5 (cg-RX-API-DMAC7.html)
JP2021529776A5 (cg-RX-API-DMAC7.html)
RU2019104896A (ru) Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и способы их использования
JP2019524111A5 (cg-RX-API-DMAC7.html)
IL320882A (en) And the uses of PSMA antibodies